CLEVELAND, Ohio — A shift toward personalized treatment for breast cancer, ways to help patients live longer without their cancer worsening and a shorter but equally effective treatment for a ...
2hon MSN
Universal, ready-to-use immunotherapy detects and destroys endometrial cancer in preclinical tests
Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech ...
Cancer is the second-leading cause of death in the United States, accounting for over 613,000 fatalities in 2023, per the Centers for Disease Control. But the field of cancer vaccines, which can be ...
A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, ...
Zacks.com on MSN
IBRX Stock Jumps on Progress in NK Cell Therapy Production
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing engineering programs for its autologous memory cytokine-enhanced natural killer ...
KFF Health News on MSN
In Switching to Original Medicare, Beware of Medigap Plan Refusals
Open enrollment season lasts until March 31 for people enrolled in Medicare Advantage who want to switch to original Medicare, but there’s a potential hitch.
Which careers related to biology? Find out the jobs available in this discipline, the qualifications, the skills needed and ...
This illustration shows targeted alpha therapy, in which actinium-225 is linked to a targeting molecule that binds to a cancer cell and delivers ...
Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options• Award ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
Lawyers are scheduled to make closing arguments at the trial of a Utah woman who published a children’s book about grief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results